NEOGENOMICS INC (NEO) Stock Price, Quote, News and Overview
NASDAQ:NEO - Nasdaq - US64049M2098 - Common Stock - Currency: USD
NEO Quote, Performance and Key Statistics
11.1
-0.76 (-6.41%)
The current stock price of NEO is 11.1 USD. In the past month the price decreased by -24.28%. In the past year, price decreased by -33.89%.
NEO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
| CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
| LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
| DVA | DAVITA INC | 14.99 | 11.68B | ||
| HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
| CHE | CHEMED CORP | 23.84 | 8.18B | ||
| CRVL | CORVEL CORP | 25.97 | 5.57B | ||
| OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.30B |
Related stock screener links
About NEO
Company Profile
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,100 full-time employees. The company went IPO on 2012-12-10. The firm offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Company Info
NEOGENOMICS INC
9490 Neogenomics Way
Fort Myers FLORIDA 33913 US
CEO: Douglas M. VanOort
Employees: 2100
Company Website: https://neogenomics.com/
Investor Relations: https://ir.neogenomics.com/
Phone: 12397680600
NEOGENOMICS INC / NEO FAQ
What is the stock price of NEOGENOMICS INC today?
The current stock price of NEO is 11.1 USD. The price decreased by -6.41% in the last trading session.
What is the ticker symbol for NEOGENOMICS INC stock?
The exchange symbol of NEOGENOMICS INC is NEO and it is listed on the Nasdaq exchange.
On which exchange is NEO stock listed?
NEO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEOGENOMICS INC stock?
19 analysts have analysed NEO and the average price target is 20.49 USD. This implies a price increase of 84.55% is expected in the next year compared to the current price of 11.1. Check the NEOGENOMICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEOGENOMICS INC worth?
NEOGENOMICS INC (NEO) has a market capitalization of 1.42B USD. This makes NEO a Small Cap stock.
How many employees does NEOGENOMICS INC have?
NEOGENOMICS INC (NEO) currently has 2100 employees.
What are the support and resistance levels for NEOGENOMICS INC (NEO) stock?
NEOGENOMICS INC (NEO) has a resistance level at 13.74. Check the full technical report for a detailed analysis of NEO support and resistance levels.
Is NEOGENOMICS INC (NEO) expected to grow?
The Revenue of NEOGENOMICS INC (NEO) is expected to grow by 10.74% in the next year. Check the estimates tab for more information on the NEO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEOGENOMICS INC (NEO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NEO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NEO, evaluating the profitability, health, valuation and growth aspects
- NEOGENOMICS INC (NEO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEOGENOMICS INC (NEO) Sales and EPS estimates to see what analysts future expectations are.
- NEOGENOMICS INC (NEO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEOGENOMICS INC (NEO) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEOGENOMICS INC (NEO) Stock Chart to make your own analysis
- NEOGENOMICS INC (NEO) Latest news and press-releases to stay up to date.
Does NEOGENOMICS INC (NEO) stock pay dividends?
NEO does not pay a dividend.
When does NEOGENOMICS INC (NEO) report earnings?
NEOGENOMICS INC (NEO) will report earnings on 2025-04-28, after the market close.
What is the Price/Earnings (PE) ratio of NEOGENOMICS INC (NEO)?
The PE ratio for NEOGENOMICS INC (NEO) is 111. This is based on the reported non-GAAP earnings per share of 0.1 and the current share price of 11.1 USD. Check the full fundamental report for a full analysis of the valuation metrics for NEO.
What is the Short Interest ratio of NEOGENOMICS INC (NEO) stock?
The outstanding short interest for NEOGENOMICS INC (NEO) is 2.97% of its float. Check the ownership tab for more information on the NEO short interest.
NEO Technical Analysis
NEO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NEO. NEO may be in some trouble as it scores bad on both profitability and health.
NEO Financial Highlights
Over the last trailing twelve months NEO reported a non-GAAP Earnings per Share(EPS) of 0.1. The EPS increased by 190.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.74% | ||
| ROE | -8.56% | ||
| Debt/Equity | 0.37 |
NEO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to NEO. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 90.15% and a revenue growth 10.74% for NEO